BC questions

This bingo card has 6 images, a free space and 24 words: This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial, This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose, Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy, Preferred regimen for HR+ disease for frail/elderly patients, The only steroidal aromatase inhibitor in its drug class, The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy, This drug class are the backbone of HR+ disease, This agent is well studied for tamoxifen induced hot flashes in breast cancer, 1%, I can give this agent in high risk BRCA 1/2 mutation for 1 year, This agent should be initiated with neratinib for the first 8 weeks, Preferred frequency of GnRH agonists, Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score, Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial, This agent can cause endometrial cancer, but has bone density protective effect, Patients with HER2+ disease continue targeted therapy for this duration, This subtype of breast cancer has the lowest relative 5-year survival rate, This should be monitored routinely every 3-4 months while receiving trastuzumab, Based on Oncotype DX, a score of 35 will receive this treatment, This treatment modality is always combined with lumpectomy surgery, This agent can be added to LN+ HER2+ disease given with trastuzumab, This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression, This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer and Duration of time patients will take abemaciclib in early stage disease.

More like this:

Supplement Bingo | Health Screening & Immunizations Bingo! | PHSA Breast Cancer Awareness Bingo | BREAST CANCER AWARENESS | Pharmacology